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Abstract: A new hypothesis is discussed, which describes the initiation of the carcinogenesis through polycyclic aromatic 
hydrocarbons (PAHs) and aminoazo dyes (AZOs) as a two-step process: the oncogenic proteins of the ras or ras-like on-
cogenes activated by mutation (“initiation A ”) co-operate with the complexes in the plasma membrane formed during the 
"initiation B " stage from the parent compounds of the PAHs or AZOs with cholesterol and apolipoprotein A-I. The final 
result of this co-operation, or the "complete initiation", is an irreversibly modified membrane architecture with negative 
consequences for growth control. 
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INTRODUCTION 
  Polycyclic aromatic hydrocarbons (PAHs) and aminoazo 
dyes (AZOs) exercise several functions as "complete car-
cinogens" in the multistep process of carcinogenesis [1, 2]:  
INITIATION  → CONVERSION → PROMOTION → 
PROGRESSION 
  Step by step, growth-inhibiting factors are degraded and 
cell growth is promoted during carcinogenesis, until a tumor 
is ultimately formed. The still almost unanimous opinion that 
exclusively genotoxic and cytotoxic metabolites of the PAHs 
and AZOs are actively involved in this multi-step process, 
and that the parent compounds remain totally inert, is in need 
of revision. The parent compounds of PAHs and AZOs can 
also be directly involved in the process of carcinogenesis, 
since in the presence of slight amounts of apolipoprotein A-I 
(apoA-I) - a principal constituent of high-density lipoprotein 
(HDL) - they form adsorption complexes with cholesterol 
and can thus change specific functions of the plasma mem-
brane and its components [3, 4]. The stability of these, pre-
sumably epitaxial complexes correlates closely with the 
carcinogenic efficacy of the PAHs or AZOs they contain, 
and is strengthened by the hydrophobicity in the intermo-
lecular interactions in the complex, but weakened by the 
aqueous solubility of the carcinogens [4]. The correlation 
with the strength of the carcinogenic efficacy leads to the 
conclusion that the parent compounds of the PAHs and 
AZOs play an essential role in the mechanism of carcino-
genesis. Up to now the actual mechanisms underlying this 
correlation have not been explained. The following ideas 
should stimulate the discussion. 
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  The results of the "complete carcinogenicity assays" (e.g. 
PAH as initiator and promoter) are in agreement with the 
"assays for tumor initiation" (e.g., PAH as initiator and cro-
ton oil or 12-O-tetradecanoylphorbol-13-acetate (TPA) as 
promoter) [5, 6]. This relationship can only be interpreted to 
mean that the relative carcinogenic efficacy of the aromates 
is largely independent from the type of convertogenic pro-
moter. In other words, the relative efficacy is already mani-
fested in these assays during the initiation of the tumorigene-
sis. The parent compounds of the carcinogenic PAHs and 
AZOs are consequently initiators. 
  The results of a multitude of animal experiments con-
ducted in the past decades with PAHs and AZOs create the 
impression that there are two different types of "initiation": 
one initiation as source of the nonautonomous benign tumors 
[e.g. papillomas (skin), nodules (liver)], and another type of 
initiation as source of autonomous malignant tumors (e.g. 
carcinomas). Primarily nonautonomous tumors develop in 
the "assay for tumor initiation" in mouse skin, whereas pri-
marily autonomous tumors develop in the "complete car-
cinogenesis assay" [5, 6].  
HYPOTHESIS 
  Two sub-steps A and B can be distinguished in the proc-
ess of initiation through PAHs and AZOs (Table 1): 
Initiation A  
  Electrophilic metabolites [7] or radical cations [8] of the 
PAHs or AZOs form a covalent bond to the bases of the 
DNA. Result: point mutations of the DNA and hence also the 
activation of proto-oncogenes to oncogenes, e.g. "ras-like" 
oncogenes [9]. Under the repeated influence of a converto-
genic promoter, e.g. TPA (skin) [1] or phenobarbital (liver) 
[2],  benign nonautonomous tumors (papillomas, nodules) 
develop from these mutated cells.  Hypothetical Two-Step Initiation of Experimental Carcinogenesis  The Open Biochemistry Journal, 2012, Volume 6    41 
Initiation B 
  Molecules of the parent compounds of PAHs and AZOs 
can form hydrophobic complexes with apoA-I and choles-
terol in the plasma membrane and thus change the membrane 
architecture [3, 4]. Such induced changes in membrane fluid-
ity or microviscosity could modulate the distribution and 
activity of membrane proteins (e.g. receptors) which are 
critical to the regulation of cellular proliferation. The forma-
tion of complexes in the plasma membrane is only a reversi-
ble event, however, and on its own presumably without long-
term effect. In contrast, a fully new situation arises when 
initiation A co-operates with initiation B at the plasma mem-
brane (see below).  
Hypothetical Co-operation: Initiation A + Initiation B 
  The formation of the complexes (initiation B) presuma-
bly also has irreversible consequences if oncogenes are acti-
vated in the same cell and whose products (oncogenic pro-
teins) are active at the same location of the plasma mem-
brane where the complexes are found. The oncogenic pro-
teins can presumably stabilize the resulting changes in archi-
tecture during the initiation B process by binding to or react-
ing with essential components. Autonomous tumors ulti-
mately develop under the repeated influence of a suitable 
promoter from these preneoplastic cells arising from a co-
operation of initiation A with initiation B (Table 1).  
DISCUSSION 
  The assumption that activated oncogenes (here initiation 
A) exclusively initiate benign nonautonomous tumors when 
on their own is not a new idea. Boukamp et al. [10] pub-
lished an equivalent hypothesis, also supported by results 
obtained after transfection and infection studies in mouse 
keratinocytes in vitro and in vivo [11, 12]. What is new here, 
however, is the hypothesis that another step is required for 
the "complete initiation" by PAHs and AZOs, brought into 
action by the parent compounds of PAHs or AZOs and re-
sulting in a changed architecture and function of the plasma 
membrane. Perhaps the co-operation of initiation A with 
initiation B with respect to their consequences is comparable 
to the longer known co-operation of ras or "ras-like” onco-
genes with myc or "myc-like” oncogenes in an in vitro cul-
ture: "myc enables ras transformants to ignore or override 
the inhibitory influences of normal neighboring cells” [9].  
  Possible initiators of an initiation B and its relative effec-
tiveness can be determined in simple in vitro short-term tests 
for PAHs and AZOs [4]. Up to now the tests have shown 
that all PAHs and AZOs with carcinogenic effect - without 
exception (!) – can be initiators of class B, with a relative 
effectiveness which correlates with their carcinogenic po-
tency. Furthermore, there are a few PAHs with false positive 
test results, such as for instance 3,9-dimethylbenz[a] anthra-
cene, triphenylene and perylene [4]. These three non-
carcinogenic PAHs are relatively strong complexing agents 
with cholesterol and apoA-I. Therefore according to the 
hypothesis presented here, one could expect them to be 
strong initiators of class B. In an “assay for tumor initiation” 
(e.g. DMBA + TPA) they should be able to raise the number 
of the autonomous tumors at the expense of the nonautono-
mous tumors. The fact that this property of the respective 
compounds has not yet been detected can probably be ex-
plained by the fact that they are already completely inactive 
as initiators of class A in a usual carcinogenicity assay, and 
thus a collaboration of initiation B with initiation A is impos-
sible under these conditions. 
  Theoretically, only one single PAH or AZO molecule is 
required for "initiation A" , i.e. for the mutation of a proto-
oncogene. In contrast, it is certain that a larger number of 
molecules is necessary for "initiation B", i.e. for the forma-
tion of crystalline complexes with cholesterol. This means 
Table 1.  Hypothetical Two-step Model of “Initiation” in the Process of Experimental Carcinogenesis by PAHs (skin) and AZOs 
(Liver) 
 Step 1  Step 2  Step 3  Step 4  Result   
-------  INITIATION B  CONVERSION  PROMOTION   No Tumors   
INITIATION A  -------  CONVERSION  PROMOTION   Nonautonomous Tumors: 
Papillomas (skin) 
Nodules (liver) 
Regression 
INITIATION A  INITIATION B  CONVERSION  PROMOTION   Persistent Tumors  Progression  
→ CANCER 
Complete Initiation  Complete Promotion   
INITIATION A: Point mutations by “ultimate carcinogens” and hence also the activation of proto-oncogenes to oncogenes [9]. 
                         Result: Among other things, the activation of oncogenes whose products are active at the plasma membrane.  
INITIATION B: Formation of PAH/cholesterol/apoA-I - or AZO/cholesterol/apoA-I complexes in the plasma membrane [3, 4]. 
          Result: Reversible changes in the membrane architecture and its functions. 
          Hypothesis: INITIATION A can co-operate with INITIATION B at the plasma membrane. See text. 
          Result: An irreversibly modified membrane architecture with negative consequences for growth control. 
          CONVERSION and PROMOTION see: Marks and Fürstenberger [1]; Schwarz [2]. 42    The Open Biochemistry Journal, 2012, Volume 6  Bodo Contag 
that the concentration of PAHs or AZOs at the place of ac-
tion must surpass a minimum level to be able to induce a 
"complete initiation". The consequences of a "complete 
initiation" would have to be expressed in vitro in an irre-
versibly changed behavior of the plasma membrane. It would 
be conceivable, for instance, that there was a reaction of the 
cell membrane with an agglutinin [13] and especially a loss 
of the "contact inhibition" of cell replication [14]. Both char-
acteristics are an expression of a cell transformation which 
would not have occurred solely by an "initiation A".  
  The “complete initiation” could modulate the distribu-
tion and activity of membrane proteins (e.g. receptors) which 
are critical to the regulation of cellular proliferation. For 
instance, the communication of the cell with its immediate 
vicinity (matrix, cells) could be impaired. Another attractive 
idea is that actin filaments detach from the adhesion plaques 
of the plasma membrane [15]. In fact, the actin filaments in 
transformed cells are fully disorganized [15]. The free actin 
filaments could lead to disturbances in the cell division, 
which would result in chromosomal abnormalities and ane-
uploidy. The chromosomal abnormalities in these cells may 
inactivate tumor suppressor genes and/or activate additional 
oncogenes. Such mechanisms remain to be investigated. 
CONCLUSION 
  The previously known course of initiation (here called 
“initiation A”), i.e. the activation of oncogenes [1, 16], is not 
challenged by this new hypothesis. But “initiation A” must 
be supplemented by an “initiation B”, that is by a change in 
architecture of the plasma membrane. The final result of a 
“complete initiation” after a co-operation between “initiation 
A” and “initiation B” is a preneoplastic cell with an irre-
versibly modified membrane architecture with negative con-
sequences for growth control. The hypothetical two-step 
model of initiation discussed here applies initially only for 
PAHs and AZOs. Concrete indications that this two-step 
model can be transferred in similar form to other complete 
carcinogens is currently under investigation. 
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